Amgen Inc. (AMGN) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

Truist’s recent upgrade of Amgen’s price target to $340 from $327 signals renewed confidence that the company’s Q2 earnings will rebound, buoyed by broader biotech sector momentum. The higher target reflects expectations that Amgen’s upcoming results could justify a stronger valuation, which may lift the stock in the next few trading days. Morgan Stanley’s modest cut of the target to $333, while keeping an equal‑weight rating, introduces some uncertainty about near‑term upside, suggesting that traders should watch for any divergence in analyst sentiment. Meanwhile, Amgen’s voluntary recall of Corlanor and Sensipar lots for foreign substances and CGMP deviations has highlighted potential quality‑control risks that could weigh on short‑term earnings and investor confidence. The recall’s impact may be mitigated if the company quickly implements corrective actions, but the ongoing issue remains a watch item for the next ten days. A federal judge’s preliminary injunction blocking Colorado’s proposed 70% price cap on Enbrel preserves the drug’s pricing flexibility, which could support revenue streams that were previously under threat. However, the FDA’s demand to remove Tavneos from the U.S. market introduces a dividend risk that could affect Amgen’s financial stability if the product is withdrawn. The combination of regulatory relief for Enbrel and execution risk from recalls creates a nuanced risk‑reward profile that traders should monitor closely. In the short term, key items to watch include the Q2 earnings release, the status of the recall remediation, Enbrel’s revenue outlook, and any further FDA actions on Tavneos.

AMGN|Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NMS

Country

United States

Website

amgen.com

Symbol

AMGN

Description

Amgen Inc. is a global biotechnology company focused on the discovery, development, manufacturing, and delivery of human therapeutics. The company's core value proposition lies in its diverse portfolio of innovative medicines designed to treat a wide range of serious illnesses. Key therapeutic areas include immunology, oncology, cardiovascular disease, bone health, and nephrology, with flagship products such as Enbrel, Repatha, and Prolia. Amgen distributes its products through healthcare providers, pharmacies, and direct-to-consumer channels, establishing a broad market reach. Strategic collaborations with other pharmaceutical companies, such as AstraZeneca and Novartis, further enhance its product pipeline and market presence, solidifying its competitive position in the biotechnology landscape.

AMGN|Earnings Snapshot

Earnings Summary

Amgen Inc. (AMGN) is a global biotechnology firm that discovers, develops, manufactures, and delivers human therapeutics across immunology, oncology, cardiovascular, bone health, and nephrology, with flagship products such as Enbrel, Repatha, and Prolia. In Q4 2025 the company posted revenue of $9.866 billion and EPS of $5.29, both exceeding estimates of $9.661 billion and $4.828 billion respectively, marking a 2.4% revenue rise from Q3 2025 and a 9.4% EPS gain; the firm also beat estimates in Q3 2025 (EPS $5.64 vs $5.015) and Q1 2026 (EPS $5.15 vs $4.767), underscoring a consistent earnings outperformance. Over the last four quarters, revenue has climbed from $8.149 billion in Q4 2024 to $9.866 billion in Q4 2025, a 21.6% YoY increase, while EPS has risen from $5.31 in Q4 2024 to $5.29 in Q4 2025, reflecting stable profitability despite a slight dip in Q1 2026 revenue to $8.618 billion. The company has maintained a pattern of beating EPS estimates in three of the last four quarters, with revenue growth largely driven by its core product pipeline and favorable pricing dynamics. Recent analyst commentary shows a mixed sentiment: Morgan Stanley trimmed its target to $333 from $340, citing modest growth expectations, while Truist Securities lifted its target to $340 from $327, reflecting confidence in the pipeline; a federal judge’s preliminary injunction blocking Colorado’s proposed 70% price cap on Enbrel has preserved pricing power, whereas a recall of certain Corlanor and Sensipar lots has introduced short‑term operational risk. Investors should watch for the upcoming Q2 2026 earnings release to gauge how the recall cost impact and Enbrel pricing relief translate into guidance, and whether any new pipeline milestones or regulatory developments emerge that could shift the company’s growth narrative.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$5.60	-	-
Q1'26	$4.77	$5.15	+8.0%
Q4'25	$4.83	$5.29	+9.6%
Q3'25	$5.01	$5.64	+12.5%
Q2'25	$5.28	$6.02	+14.1%
Q1'25	$4.26	$4.90	+15.0%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$9.6B	-	-
Q1'26	$8.6B	$8.6B	+0.5%
Q4'25	$9.7B	$9.9B	+2.1%
Q3'25	-	$9.6B	-
Q2'25	-	$9.2B	-
Q1'25	-	$8.1B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

AMGN Stock Snapshot

AMGN is currently trading at $361.61, giving Amgen Inc. a market cap of 196.12B and a P/E ratio of 25.1. Today's range spans $361.14–$368.06, with shares opening at $363.08 and moving down $1.78 (0.5%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 70/100.

Over the past year AMGN has traded between $269.77 and $391.29 - the current price is +34.0% off the 52-week low and -7.6% from the high. 43 analysts cover the stock with a Hold consensus and a mean 12-month target of $355.66 (range $215.00–$427.00), implying downside of -1.6%.

AMGN is showing the kind of bullish setup that active managers add to on dips - 82/100 (BUY), bullish sentiment at 70/100, 196.12B market cap in Healthcare, price $361.61 (in the upper portion of its 52-week range). The current P/E ratio stands at 25.1. At this cap tier, the combination of technical confirmation and positive sentiment is what separates speculative bullish positions from high-conviction ones. Annual range: $269.77–$391.29. The setup is in the latter category.

What makes AMGN's BUY setup (82/100) particularly actionable at 196.12B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $361.61 (in the upper portion of its 52-week range in $269.77–$391.29), with sentiment running bullish at 70/100, the setup rewards conviction-sized positioning more than it does speculative small bets.

News Sentiment Analysis

Sentiment gathered from recent headlines

70/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Truist has increased its price target for Amgen to $340 from $327, reflecting optimism about a rebound in the biotech sector. The upgrade comes as part of a broader Q2 earnings preview, suggesting that Amgen’s upcoming results could support the higher valuation. Traders should keep an eye on the Q2 earnings release and any new product or regulatory developments that could influence the stock’s trajectory.

What did this article say?

No summary available yet for this article.

What did this article say?

Amgen's share price remains in line with the broader market, posting a 12% gain over the past six months. The S&P 500 returned 7.7% during the same period, indicating AMGN outperformed the index. The stock trades at $365.22 per share, reflecting its valuation relative to peers. Investors may view this as a sign of steady performance amid market volatility. Watch for upcoming earnings and guidance to assess future upside.

What did this article say?

No summary available yet for this article.

What did this article say?

Morgan Stanley has reduced its price target for Amgen (AMGN) from $340 to $333 while maintaining an equal‑weight rating. The downgrade reflects a modest reassessment of the company’s near‑term prospects, though the overall outlook remains neutral. Amgen’s average analyst rating is still overweight, with a mean target of $356 across the market. The change may influence short‑term trading activity but does not signal a major shift in fundamentals.

What did this article say?

Amgen (AMGN) announced voluntary nationwide recalls of certain Corlanor and Sensipar tablet lots due to foreign substances and CGMP deviations. Despite the quality‑control setback, the stock has maintained a 5.3% return over the past 30 days and a 12.35% year‑to‑date gain, indicating investor confidence. Analysts note the shares trade modestly above consensus targets yet remain discounted relative to some intrinsic value models. The recall raises compliance risk but may be viewed as a temporary issue that could leave upside potential if resolved swiftly.

What did this article say?

In early June 2026, a federal judge granted Amgen a preliminary injunction blocking Colorado’s proposed 70% price cap on its rheumatoid arthritis drug Enbrel, preserving pricing flexibility for the product. At the same time, Amgen voluntarily initiated Class II recalls of Corlanor and Sensipar batches in the United States due to foreign substances and CGMP deviations. The juxtaposition of regulatory relief and execution risk creates a nuanced risk‑reward profile for investors. Traders should monitor the impact on Enbrel revenue and any additional quality‑control findings that could affect the company’s cost structure.

What did this article say?

Amgen is facing a regulatory challenge as the FDA demands the removal of Tavneos from the U.S. market due to alleged manipulation of clinical trial data. The potential withdrawal could strain the company’s ability to maintain its dividend program. Amgen recently secured a court victory against Colorado regulators attempting to cap the price of Enbrel, but the FDA dispute remains unresolved. Investors should monitor how the FDA decision and any subsequent regulatory actions affect Amgen’s financial stability and dividend outlook.

What did this article say?

Amgen has initiated multiple product recalls for Sensipar and Corlanor across several lots and dosage strengths nationwide. The recalls stem from CGMP deviations and contamination concerns identified by regulators. The pattern of recurring recalls indicates potential systemic quality control issues that could impact sales and regulatory scrutiny. Investors should monitor Amgen's remediation plans and any subsequent regulatory actions. The recalls may weigh on short‑term earnings and investor sentiment. The company’s ability to address quality issues will be a key factor in future performance.

What did this article say?

Truist Securities has increased its price target for AMGN to $340 from $327, reflecting a bullish outlook. The brokerage cites improved earnings guidance and a favorable pipeline outlook as key drivers. Traders should monitor upcoming earnings and any regulatory updates that could influence the target.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

No summary available yet for this article.

What did this article say?

No summary available yet for this article.

What did this article say?

AMGN·Amgen Inc.

EPS

Revenue

AMGN Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More